Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry
This is an overview of where and by who this paper has been cited.
Help Us
Non-profit projects normally ask for donations. We don't. We will survive one way or another. If you wish to help us, please spread the word to let more people use this service.
It is delightful to see our efforts are useful to a broad range of researchers.
